首页/数据集/Booster dose of self-amplifying SARS-CoV-2 RNA vaccine vs. mRNA vaccine: a phase 3 comparison of ARCT-154 with Comirnaty®

Booster dose of self-amplifying SARS-CoV-2 RNA vaccine vs. mRNA vaccine: a phase 3 comparison of ARCT-154 with Comirnaty®

NCATS Open Data2023-07-21 更新2026-08-08 收录

疫苗临床试验

COVID-19疫苗加强剂

数据链接：

https://doi.org/10.1101/2023.07.13.23292597 数据链接链接失效反馈

官方服务：

资源简介：

Booster dose of self-amplifying SARS-CoV-2 RNA vaccine vs. mRNA vaccine: a phase 3 comparison of ARCT-154 with Comirnaty®

应用场景：

创建时间：

2023-07-13

癌症免疫治疗

疫苗临床试验

BackgroundImmune checkpoint blockade with monoclonal antibodies targeting programmed death 1 (PD-1) and its ligand PD-L1 has played a major role in the rise of cancer immune therapy. We have identifie

NIAID Data Ecosystem70

Characteristics of HVTN 502 and 503 trial participants.

疫苗临床试验

免疫基因型分析

Data shown are median values (interquartile range) unless otherwise indicated. * At time of sampling § HLA-B*27, B51, B*5701/03, B*5801 and B*8101 Characteristics of HVTN 502 and 503 trial participant

NIAID Data Ecosystem20

Dataset from Partially-blind Immunogenicity and Safety Study of GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults.

疫苗临床试验

免疫原性评估

This study is designed to assess the safety and immunogenicity of a GSK Biologicals' investigational vaccine GSK2321138A in adults 18 years old and older. This study is also designed to assess the lot

NIAID Data Ecosystem20

Predictors of consenting to mucosal secretion sampling amongst volunteers screened for HVTN 097.

疫苗临床试验

生物样本采集行为预测

*OR = Odds Ratio. **95% CI = 95% confidence interval. †AOR = Adjusted Odds Ratio. Predictors of consenting to mucosal secretion sampling amongst volunteers screened for HVTN 097.

NIAID Data Ecosystem30

Dataset from Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy Infants

疫苗临床试验

结核病预防

This purpose of the study is to assess the safety and immunogenicity of a GSK Biologicals' candidate tuberculosis vaccine (692342) when administered concomitantly with or after the Expanded Programme

NIAID Data Ecosystem20

Booster dose of self-amplifying SARS-CoV-2 RNA vaccine vs. mRNA vaccine: a phase 3 comparison of ARCT-154 with Comirnaty®

资源简介：

相关数据集